Latest News for: igf 1r

Edit

Minghui Pharmaceutical and ASKA Pharmaceutical Enter into Exclusive License Agreement for the IGF-1R Antibody in Japan

PR Newswire 04 Nov 2026
MHB018A is a novel, subcutaneously administered antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for the treatment of thyroid eye disease (TED) ... It is designed to inhibit IGF-1R ...
Edit

Sling Therapeutics Announces Publication of New Data Highlighting Differentiated Mechanism of Action of Oral IGF-1R Inhibitor Linsitinib in Thyroid Eye Disease (Forbion Capital Partners Management Services BV)

Public Technologies 02 Nov 2026
Linsitinib is an investigational, oral, small-molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and is currently being evaluated in the pivotal Phase 3 ORBIT trial in adults with moderate to severe active TED.
Edit

Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease (Forbion Capital Partners Management Services BV)

Public Technologies 16 Sep 2026
Proceeds from the financing will support the continued clinical advancement of linsitinib, an oral small molecule inhibitor of IGF-1R (insulin-like growth factor 1 receptor), a validated target for the treatment of TED.
  • 1
×